Literature DB >> 19564412

The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability.

Antonietta Rosella Farina1, Antonella Tacconelli, Lucia Cappabianca, Gesilia Cea, Sonia Panella, Antonella Chioda, Alessandra Romanelli, Carlo Pedone, Alberto Gulino, Andrew Reay Mackay.   

Abstract

The hypoxia-regulated alternative TrkAIII splice variant expressed by human neuroblastomas exhibits oncogenic potential, driven by in-frame exon 6 and 7 alternative splicing, leading to omission of the receptor extracellular immunoglobulin C(1) domain and several N-glycosylation sites. Here, we show that the TrkAIII oncogene promotes genetic instability by interacting with and exhibiting catalytic activity at the centrosome. This function depends upon intracellular TrkAIII accumulation and spontaneous interphase-restricted activation, in cytoplasmic tyrosine kinase (tk) domain orientation, predominantly within structures that closely associate with the fully assembled endoplasmic reticulum intermediate compartment and Golgi network. This facilitates TrkAIII tk-mediated binding of gamma-tubulin, which is regulated by endogenous protein tyrosine phosphatases and geldanamycin-sensitive interaction with Hsp90, paving the way for TrkAIII recruitment to the centrosome. At the centrosome, TrkAIII differentially phosphorylates several centrosome-associated components, increases centrosome interaction with polo kinase 4, and decreases centrosome interaction with separase, the net results of which are centrosome amplification and increased genetic instability. The data characterize TrkAIII as a novel internal membrane-associated centrosome kinase, unveiling an important alternative mechanism to "classical" cell surface oncogenic receptor tk signaling through which stress-regulated alternative TrkAIII splicing influences the oncogenic process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19564412      PMCID: PMC2725721          DOI: 10.1128/MCB.00352-09

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

1.  A genomic view of alternative splicing.

Authors:  Barmak Modrek; Christopher Lee
Journal:  Nat Genet       Date:  2002-01       Impact factor: 38.330

Review 2.  The Golgi apparatus at the cell centre.

Authors:  Rosa M Rios; Michel Bornens
Journal:  Curr Opin Cell Biol       Date:  2003-02       Impact factor: 8.382

Review 3.  Oncogenes and tumour suppressors take on centrosomes.

Authors:  Kenji Fukasawa
Journal:  Nat Rev Cancer       Date:  2007-12       Impact factor: 60.716

4.  Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells.

Authors:  Angelika Eggert; Michael A Grotzer; Naohiko Ikegaki; Xing-ge Liu; Audrey E Evans; Garrett M Brodeur
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

5.  The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts.

Authors:  T Takahashi; M Shibuya
Journal:  Oncogene       Date:  1997-05-01       Impact factor: 9.867

6.  Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.

Authors:  S C Onuoha; S R Mukund; E T Coulstock; B Sengerovà; J Shaw; S H McLaughlin; S E Jackson
Journal:  J Mol Biol       Date:  2007-06-29       Impact factor: 5.469

Review 7.  Unconventional splicing of XBP-1 mRNA in the unfolded protein response.

Authors:  Hiderou Yoshida
Journal:  Antioxid Redox Signal       Date:  2007-12       Impact factor: 8.401

8.  JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

Authors:  Isabelle Plo; Mayuka Nakatake; Laurent Malivert; Jean-Pierre de Villartay; Stéphane Giraudier; Jean-Luc Villeval; Lisa Wiesmuller; William Vainchenker
Journal:  Blood       Date:  2008-05-30       Impact factor: 22.113

9.  Direct targeting of cis-Golgi matrix proteins to the Golgi apparatus.

Authors:  S I Yoshimura; N Nakamura; F A Barr; Y Misumi; Y Ikehara; H Ohno; M Sakaguchi; K Mihara
Journal:  J Cell Sci       Date:  2001-11       Impact factor: 5.285

10.  Centrosome cohesion is regulated by a balance of kinase and phosphatase activities.

Authors:  P Meraldi; E A Nigg
Journal:  J Cell Sci       Date:  2001-10       Impact factor: 5.285

View more
  14 in total

1.  Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4.

Authors:  Karuna Mittal; Jaspreet Kaur; Shaligram Sharma; Nivya Sharma; Guanhao Wei; Ishita Choudhary; Precious Imhansi-Jacob; Nagini Maganti; Shrikant Pawar; Padmashree Rida; Michael S Toss; Mohammed Aleskandarany; Emiel A Janssen; Håvard Søiland; Meenakshi V Gupta; Michelle D Reid; Emad A Rakha; Ritu Aneja
Journal:  Mol Cancer Res       Date:  2022-04-01       Impact factor: 6.333

Review 2.  Neurotrophin signaling in cancer stem cells.

Authors:  Valérie Chopin; Chann Lagadec; Robert-Alain Toillon; Xuefen Le Bourhis
Journal:  Cell Mol Life Sci       Date:  2016-02-17       Impact factor: 9.261

3.  TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma.

Authors:  Luciana Gneo; Pierdomenico Ruggeri; Lucia Cappabianca; Antonietta Rosella Farina; Natalia Di Ianni; Andrew Reay Mackay
Journal:  Oncotarget       Date:  2016-12-06

4.  TrkAIII signals endoplasmic reticulum stress to the mitochondria in neuroblastoma cells, resulting in glycolytic metabolic adaptation.

Authors:  Antonietta Rosella Farina; Lucia Cappabianca; Luciana Gneo; Pierdomenico Ruggeri; Andrew Reay Mackay
Journal:  Oncotarget       Date:  2017-12-22

Review 5.  The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.

Authors:  Antonietta Rosella Farina; Lucia Cappabianca; Pierdomenico Ruggeri; Luciana Gneo; Cristina Pellegrini; Maria-Concetta Fargnoli; Andrew Reay Mackay
Journal:  J Exp Clin Cancer Res       Date:  2018-06-18

6.  Sources of contradictions in the evaluation of population genetic consequences after the chernobyl disaster.

Authors:  V I Glazko; T T Glazko
Journal:  Acta Naturae       Date:  2013-01       Impact factor: 1.845

7.  TrkAIII promotes microtubule nucleation and assembly at the centrosome in SH-SY5Y neuroblastoma cells, contributing to an undifferentiated anaplastic phenotype.

Authors:  Antonietta R Farina; Natalia Di Ianni; Lucia Cappabianca; Pierdomenico Ruggeri; Marzia Ragone; Giulia Ianni; Alberto Gulino; Andrew R Mackay
Journal:  Biomed Res Int       Date:  2013-06-06       Impact factor: 3.411

8.  The TrkAIII oncoprotein inhibits mitochondrial free radical ROS-induced death of SH-SY5Y neuroblastoma cells by augmenting SOD2 expression and activity at the mitochondria, within the context of a tumour stem cell-like phenotype.

Authors:  Pierdomenico Ruggeri; Antonietta R Farina; Natalia Di Ianni; Lucia Cappabianca; Marzia Ragone; Giulia Ianni; Alberto Gulino; Andrew R Mackay
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

9.  Novel transcripts reveal a complex structure of the human TRKA gene and imply the presence of multiple protein isoforms.

Authors:  Kristi Luberg; Rahel Park; Elina Aleksejeva; Tõnis Timmusk
Journal:  BMC Neurosci       Date:  2015-11-18       Impact factor: 3.288

10.  Retrograde TrkAIII transport from ERGIC to ER: a re-localisation mechanism for oncogenic activity.

Authors:  Antonietta Rosella Farina; Lucia Cappabianca; Pierdomenico Ruggeri; Luciana Gneo; Rita Maccarone; Andrew Reay Mackay
Journal:  Oncotarget       Date:  2015-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.